The Effect of Cyclidrol(Mucoflux<sup>(R)</sup>) as a Mucolytic Agent in Respiratory Diseases

Sohn, Hee Young; Chang, Joon; Chang, Yang Soo; Chang, Sang Ho; Kim, Sung Kyu; Kim, Ki Ho

doi:1984.31.3.116

Tuberc Respir Dis > Volume 31(3); 1984 > Article

Original Article

Tuberculosis and Respiratory Diseases 1984;31(3):116-120.
DOI: https://doi.org/10.4046/trd.1984.31.3.116 Published online September 1, 1984.

The Effect of Cyclidrol(Mucoflux^(R)) as a Mucolytic Agent in Respiratory Diseases

Hee Young Sohn, Joon Chang, Yang Soo Chang, Sang Ho Chang, Sung Kyu Kim, Ki Ho Kim

Department of Internal Medicine, Yonsei University, College of Medicine, Seoul, Korea

호흡기질환의 치료에 있어서 Cyclidrol (Mucoflux^(R))의 거담효과

손희영, 장준, 장양수, 장상호, 김성규, 김기호

Abstract

Forty patients with various respiratory diseases underwent a 7-day treatment using either cyclidrol 400 mg a day or placebo in the same dose and shape. Tests aimed to evaluate the time course of respiratory symptoms. Parameters such as sputum amount, thickness, purulence, difficulty in expectoration and cough were scored in 4 scale and recorded before and after 7-days’ treatment. Symptoms revealing bronchial cleansing action such as expectoration and easiness of cough were more significantly improved in experimental group than in control group(p<0.001 vs p<0.05). And sputum thickness, the indirect index of sputum viscosity was much lowered also in experimental group(p< 0.05). Furthermore overall efficacy was estimated according to the total score of 5 items in an individual patients. Responders(excellent and good result) was 70% in experimental group, whereas 25% in control group(exact probability p=0.001). Therefore cyclidrol, according to the previous reports, to be a good oral mucolytic agent to cleanse diseased airway.